316 related articles for article (PubMed ID: 28916198)
1. Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer - final results from the prospective German TLK cohort study.
von Verschuer U; Schnell R; Tessen HW; Eggert J; Binninger A; Spring L; Jänicke M; Marschner N;
Lung Cancer; 2017 Oct; 112():216-224. PubMed ID: 28916198
[TBL] [Abstract][Full Text] [Related]
2. Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study.
Steffens CC; Elender C; Hutzschenreuter U; Dille S; Binninger A; Spring L; Jänicke M; Marschner N;
Lung Cancer; 2019 Apr; 130():216-225. PubMed ID: 30885347
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study.
Smit E; Moro-Sibilot D; Carpeño Jde C; Lesniewski-Kmak K; Aerts J; Villatoro R; Kraaij K; Nacerddine K; Dyachkova Y; Smith KT; Girvan A; Visseren-Grul C; Schnabel PA
Lung Cancer; 2016 Feb; 92():35-40. PubMed ID: 26775594
[TBL] [Abstract][Full Text] [Related]
4. Clinical decision-making and health-related quality of life during first-line and maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC): findings from a real-world setting.
Sztankay M; Giesinger JM; Zabernigg A; Krempler E; Pall G; Hilbe W; Burghuber O; Hochmair M; Rumpold G; Doering S; Holzner B
BMC Cancer; 2017 Aug; 17(1):565. PubMed ID: 28835219
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis.
Griesinger F; Korol EE; Kayaniyil S; Varol N; Ebner T; Goring SM
Lung Cancer; 2019 Sep; 135():196-204. PubMed ID: 31446995
[TBL] [Abstract][Full Text] [Related]
6. A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).
Zhou Q; Song Y; Zhang X; Chen GY; Zhong DS; Yu Z; Yu P; Zhang YP; Chen JH; Hu Y; Feng GS; Song X; Shi Q; Yang LL; Zhang PH; Wu YL
BMC Cancer; 2017 Jul; 17(1):462. PubMed ID: 28673332
[TBL] [Abstract][Full Text] [Related]
7. Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study).
Moro-Sibilot D; Audigier-Valette C; Merle P; Quoix E; Souquet PJ; Barlesi F; Chouaid C; Molinier O; Bennouna J; Lavolé A; Mazières J; Toffart AC; Langlais A; Morin F; Zalcman G
Lung Cancer; 2015 Aug; 89(2):139-45. PubMed ID: 26059274
[TBL] [Abstract][Full Text] [Related]
8. Effect of Brain Metastasis on Patient-Reported Outcomes in Advanced NSCLC Treated in Real-World Community Oncology Settings.
Walker MS; Wong W; Ravelo A; Miller PJE; Schwartzberg LS
Clin Lung Cancer; 2018 Mar; 19(2):139-147. PubMed ID: 29103883
[TBL] [Abstract][Full Text] [Related]
9. Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy.
Grønberg BH; Sundstrøm S; Kaasa S; Bremnes RM; Fløtten O; Amundsen T; Hjelde HH; Plessen Cv; Jordhøy M
Eur J Cancer; 2010 Aug; 46(12):2225-34. PubMed ID: 20471248
[TBL] [Abstract][Full Text] [Related]
10. Non-small cell lung cancer patients with brain metastases treated with first-line platinum-doublet chemotherapy: Analysis from the European FRAME study.
Moro-Sibilot D; Smit E; de Castro Carpeño J; Lesniewski-Kmak K; Aerts JG; Villatoro R; Kraaij K; Nacerddine K; Dyachkova Y; Smith KT; Girvan A; Visseren-Grul C; Schnabel PA
Lung Cancer; 2015 Dec; 90(3):427-32. PubMed ID: 26791802
[TBL] [Abstract][Full Text] [Related]
11. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
[TBL] [Abstract][Full Text] [Related]
12. Quality of life, symptom status and physical performance in patients with advanced non-small cell lung cancer undergoing chemotherapy: an exploratory analysis of secondary data.
Shallwani SM; Simmonds MJ; Kasymjanova G; Spahija J
Lung Cancer; 2016 Sep; 99():69-75. PubMed ID: 27565917
[TBL] [Abstract][Full Text] [Related]
13. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
Belani CP; Fossella F
Cancer; 2005 Dec; 104(12):2766-74. PubMed ID: 16288485
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).
Zappa F; Droege C; Betticher D; von Moos R; Bubendorf L; Ochsenbein A; Gautschi O; Oppliger Leibundgut E; Froesch P; Stahel R; Hess T; Rauch D; Schmid P; Mayer M; Crowe S; Brauchli P; Ribi K; Pless M;
Lung Cancer; 2012 Dec; 78(3):239-44. PubMed ID: 23009726
[TBL] [Abstract][Full Text] [Related]
15. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
Jiang J; Liang X; Zhou X; Huang R; Chu Z
Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
[TBL] [Abstract][Full Text] [Related]
16. Retrospective evaluation of thromboembolic events in patients with non-small cell lung cancer treated with platinum-based chemotherapy.
Mellema WW; van der Hoek D; Postmus PE; Smit EF
Lung Cancer; 2014 Oct; 86(1):73-7. PubMed ID: 25129368
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial.
Sundstrøm S; Bremnes R; Aasebø U; Aamdal S; Hatlevoll R; Brunsvig P; Johannessen DC; Klepp O; Fayers PM; Kaasa S
J Clin Oncol; 2004 Mar; 22(5):801-10. PubMed ID: 14990635
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer.
Spigel DR; Anthony Greco F; Waterhouse DM; Shipley DL; Zubkus JD; Bury MJ; Webb CD; Hart LL; Gian VG; Infante JR; Burris HA; Hainsworth JD
Lung Cancer; 2012 Oct; 78(1):70-5. PubMed ID: 22947511
[TBL] [Abstract][Full Text] [Related]
19. First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: a quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale.
Gebbia V; Lorusso V; Galetta D; Caruso M M; Palomba G; Riccardi F; Borsellino N; Carrozza F; Leo S; Ferraù F; Cinieri S; Mancuso G; Mancarella S; Colucci G
Lung Cancer; 2010 Aug; 69(2):218-24. PubMed ID: 19910076
[TBL] [Abstract][Full Text] [Related]
20. Assessment of quality of life in patients with advanced non-small cell lung carcinoma treated with a combination of carboplatin and paclitaxel.
Avelino CU; Cardoso RM; Aguiar SS; Silva MJ
J Bras Pneumol; 2015; 41(2):133-42. PubMed ID: 25972967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
